Navigation Links
Human Genome Sciences Announces First Quarter 2009 Financial Results and Key Developments
Date:4/29/2009

lfa-2a) in ACHIEVE 1, a Phase 3 clinical trial of Albuferon in treatment-naive patients with genotype 1 chronic hepatitis C. As previously reported, Albuferon also met its primary endpoint in ACHIEVE 2/3, which was conducted in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.

The results of both trials were presented on April 25 in the late-breaker session at the 44th annual meeting of the European Association for the Study of the Liver (EASL) in Copenhagen. The Phase 3 data demonstrate that, with half as many injections, in two pivotal Phase 3 trials, Albuferon achieved efficacy comparable to Pegasys with a positive safety profile. The submission of global marketing applications for Albuferon is planned in fall 2009, following discussions with the FDA and other regulatory authorities. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

LymphoStat-B(R) Phase 3 Results Expected in July and November 2009

HGS expects to report the first Phase 3 data for LymphoStat-B (belimumab) in July 2009 from the BLISS-52 trial, with results from BLISS-76 anticipated in November 2009. BLISS-52 and BLISS-76 are the largest clinical trials ever conducted in lupus patients. LymphoStat-B is being developed by HGS and GSK under a co-development and commercialization agreement entered into in August 2006.

$9 Million Milestone Payment Received from GSK Following Initiation of Phase 3 Development of Syncria(R)

HGS received a $9.0 million milestone payment during the first quarter of 2009, following GSK's initiation of a Phase 3 clinical trial program to evaluate Syncria (albiglutide) in the long-term treatment of type 2 diabetes mellitus. Syncria was created by HGS using its proprietary albumin-fusion technology, and licensed to GSK in 2004. HGS is entitled t
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... (PRWEB) May 21, 2013 Savoury Systems ... has appointed Dale Braddy to Southeastern USA Sales Broker. ... its sales muscle in the Southeast. , ... ingredient brokerage and supplier to food processors and industrial ... years in the food industry and has over 25 ...
(Date:5/21/2013)... , May 21, 2013 According ... Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services Market ... - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," ... 2011 and is expected to grow at a CAGR ... estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... 2013 Emerson Resources Inc. , ... Charles Signorino, the Company’s Chief Executive Officer and Chairman ... 32 years of service. As part of Emerson Resources’ ... has been named as Dr. Signorino’s successor. , ... industry, having made a significant contribution to the field ...
(Date:5/21/2013)... , May 21, 2013  Personal Genome Diagnostics ... its proprietary methodologies and expertise in genomic analysis ... targets in collaboration with Blueprint Medicines.  PGDx is ... identifying genomic alterations in tumors, and Blueprint Medicines ... inhibitors for a genetically defined patient population. ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 2Personal Genome Diagnostics And Blueprint Medicines Form Collaboration to Identify Novel Kinase Targets 3
... Up in the sky. It's a bird. It's a plane. It's ... denial in a single bound. Indeed, lately the media has been ... to result from the mass exodus of Baby Boomers from the ... believe that this trend and its impacts on businesses are black ...
... Milwaukee, Wis. - The National Cancer Institute ... Medical College of Wisconsin to study the growth ... second successful renewal of the grant that was first awarded ... ongoing principal investigator. , ,She and other investigators are developing ...
... This is the ninth in a series of articles ... sectors. The most recent article focused on worker classification. ... The idea is developed. Lawyers and accountants are on ... is formed. The name has been chosen. Perhaps workers, ...
Cached Biology Technology:Shades of gray: Business impacts of an aging workforce 2Shades of gray: Business impacts of an aging workforce 3Shades of gray: Business impacts of an aging workforce 4Shades of gray: Business impacts of an aging workforce 5Shades of gray: Business impacts of an aging workforce 6Early Stage, Step 9: Raising capital in the securities landscape 2Early Stage, Step 9: Raising capital in the securities landscape 3Early Stage, Step 9: Raising capital in the securities landscape 4
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
(Date:5/21/2013)... The American Chemical Society (ACS), the world,s largest ... 246th National Meeting & Exposition, September 8-12, 2013, ... the Indiana Convention Center and at area hotels. ... discoveries that span science,s horizons from astronomy ... broadcast and online journalists a rich assortment of ...
(Date:5/21/2013)... way genes function without changing the underlying DNA ... of pregnant women during any trimester, potentially providing ... weeks after giving birth, and an opportunity to ... of the small study involving 52 pregnant women ... Psychiatry . , "Postpartum depression can be harmful ...
Breaking Biology News(10 mins):MU researchers develop radioactive nanoparticles that target cancer cells 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3
... (MRSA) in swine and swine workers in the United States ... The investigators found a strain of MRSA, known as ST398, ... the paper published online Jan. 23 by the science journal ... of swine by MRSA was very common in one of ...
... 22, 2009 -- The Damon Runyon Cancer Research Foundation announced ... cancer have won the 2009 Damon Runyon-Rachleff Innovation Awards. ... year to three projects by early-career scientists that have the ... and treatment of cancer. The 2009 ...
... University] Brown University researchers have identified a cellular ... The finding by Stephen Helfand and Nicola Neretti ... Helfand, a professor of biology, molecular biology, cell biology ... identified a mutation in the Indy ("I,m Not Dead ...
Cached Biology News:Study finds MRSA in Midwestern swine, workers 22009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 22009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 32009 Damon Runyon-Rachleff Innovation Awards granted for pioneering ideas in cancer research 4Scientists unlock possible aging secret in genetically altered fruit fly 2
... The Bio-Plex suspension array system, 100-240 ... technology) for simultaneous quantitative analysis of up ... single microplate well. The suspension array is ... sets, each of which may be conjugated ...
Cell Culture Flask, 75 cm, nontreated polystyrene...
... system uses two Adept CE 4100 high ... 4200 dual wavelength detector for added flexibility. ... PowerStream data processing software and interface unit, CE ... The supplied analytical pumps may be substituted by ...
... is ideal for routine binary separations. Excellent ... CE 4201 UV-Visible variable wavelength detector. Ultra-fine ... the two highly accurate and precise, high ... delivery pumps., Chromatograms may be plotted on a ...
Biology Products: